Feature Articles

Feature Articles

ASH Clinical News takes a deeper look at hot topics in medicine

Classical Hematology: A Specialty in Decline?

As workforce shortages persist, this ancient art is undergoing a modern renaissance. Two factors influenced Alfred Ian Lee, MD, PhD, to specialize in classical hematology....

The Drug Shortages Dilemma

In hematology/oncology, drug shortages typically affect older, less expensive drugs, but when no alternatives are available, clinicians may struggle to provide the best care. It’s...

The Preservation Conversation

Discussions about possible infertility in young patients with cancer should happen early, and often. Chemotherapy, radiation, and hematopoietic cell transplantation (HCT) are essential treatment options...

The Eye of a Survivor

While cure remains a goal, unique issues arise when treating professional and amateur athletes for hematologic conditions. Athletic competition on an elite level depends on...

Transforming Ideas into Research Reality

Participants come to the ASH Clinical Research Training Institute with ideas and enthusiasm, and leave with new skills to conduct patient-oriented research. Just 20 years...

Breaking Down Barriers, Building Up Trust

Clinical trial enrollment has lacked diversity since the start, but a global racial reckoning has brought new attention to overcoming discrimination. According to the most...

Pain Pointers

Early intervention and careful management are critical in the treatment of peripheral neuropathy Peripheral neuropathy is a common occurrence in patients with hematologic diseases, whether...

Gene Therapy: The Comeback Kid of Hematology Treatments?

Despite slow progress and unexpected setbacks, the future of gene therapy remains bright. Ashanthi de Silva was the first human to be treated successfully with...

Four of a Kind?

Soon, there may be as many as four JAK inhibitors available for patients with myelofibrosis. For many of his patients with myelofibrosis, ruxolitinib has been...

Cellular Therapies Hold Promise in Myeloid Malignancies

There is hope that these therapies will improve outcomes, but development is still in early stages.  A recent spate of approvals of targeted treatments, such...
Advertisement

Current Issue

October 2021, Volume 7, Issue 12

This issue tells the long story of drug shortages, demystifies transfusion services, and more.

Block title